The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
The global Biosimilar Pipeline Analysis market is expected to grow at 17.8% CAGR from 2025 to 2032. Latest Research Report on the Biosimilar Pipeline Analysis Market Size, Status, and Forecast for ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...
4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...
Pharmaceutical Technology on MSN13d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.
NEW YORK, February 04, 2025 -- ( BUSINESS WIRE )--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback